Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Sato Pharmaceutical Co. Ltd. currently manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners and are all concentrated within 1 distinct art unit. This concentration in 1 distinct art unit suggests that the company's pharmaceutical filings are technically similar and are being reviewed by the same specialized group. The use of only 2 distinct examiners for 3 pending office actions indicates a high degree of examiner overlap within this specific technical category.
WELLS, LAUREN QUINLAN is the busiest examiner for the company, overseeing 2 pending office actions. This means that 2 of the 3 pending office actions are under the review of a single individual. The other distinct examiner handles the remaining pending matter. For practitioners, the focus on 1 distinct art unit and the concentration under WELLS, LAUREN QUINLAN provides a streamlined environment for prosecution, where arguments and strategies can be consistently applied across the 3 pending office actions. This structure allows for a more cohesive approach to the company's biotechnology and pharmaceutical intellectual property, leveraging the shared 1 distinct art unit to maintain consistency.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 2 | 48.4% | +60.3% |
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19239326 | NASAL COMPOSITION | WELLS, LAUREN QUINLAN | 42d |
| 18719703 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | KWON, YONG SOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18638204 | NASAL COMPOSITION | WELLS, LAUREN QUINLAN | 28d |
| 19239326 | NASAL COMPOSITION | WELLS, LAUREN QUINLAN | 42d |
| 18719703 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | KWON, YONG SOK | — |
| Art Unit | Apps |
|---|---|
| 1622 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19239326 | NASAL COMPOSITION | WELLS, LAUREN QUINLAN | 1622 | §102§103 | Final Rejection | 42d | Pending | Jun 16, 2025 |
| 18719703 | AZAINDOLE DERIVATIVE THAT INHIBITS H-PGDS | KWON, YONG SOK | — | §112DP | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18638204 | NASAL COMPOSITION | WELLS, LAUREN QUINLAN | 1622 | §102 | Final Rejection | 28d | Pending | Apr 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial